Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study.

[1]  L. Tavazzi,et al.  Effects of n‐3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI‐HF trial , 2010, European journal of heart failure.

[2]  T. Trikalinos,et al.  Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. , 2010, Journal of the American College of Cardiology.

[3]  S. Anker,et al.  Relation of left ventricular ejection fraction and functional capacity with metabolism and inflammation in chronic heart failure with reduced ejection fraction (from the MIMICA Study). , 2010, The American journal of cardiology.

[4]  Y. Zhao,et al.  Effects of n-3 Polyunsaturated Fatty Acid Therapy on Plasma Inflammatory Markers and N-Terminal Pro-brain Natriuretic Peptide in Elderly Patients with Chronic Heart Failure , 2009, The Journal of international medical research.

[5]  P. Calder.  Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. , 2009, Biochimie.

[6]  W. Harris,et al.  Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. , 2009, Cardiovascular research.

[7]  Gissi-Hf Investigators.  Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[8]  G. McVeigh,et al.  A randomised interventional trial of ω-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus , 2007, Annals of the rheumatic diseases.

[9]  S. Pepe,et al.  (n-3) Long chain PUFA dose-dependently increase oxygen utilization efficiency and inhibit arrhythmias after saturated fat feeding in rats. , 2007, The Journal of nutrition.

[10]  A. Coats,et al.  Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction. Recommendations for performance and interpretation , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[11]  A. Cohen-Solal,et al.  Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction. Part II: Interpretation of cardiopulmonary exercise testing in chronic heart failure and future applications. , 2006 .

[12]  J. Kjekshus,et al.  Effect of Thalidomide on Cardiac Remodeling in Chronic Heart Failure: Results of a Double-Blind, Placebo-Controlled Study , 2005, Circulation.

[13]  Jeroen J. Bax,et al.  Left Ventricular Reverse Remodeling but Not Clinical Improvement Predicts Long-Term Survival After Cardiac Resynchronization Therapy , 2005, Circulation.

[14]  J. Cohn,et al.  Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. , 2004, Journal of the American College of Cardiology.

[15]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[16]  R. Christon.  Mechanisms of action of dietary fatty acids in regulating the activation of vascular endothelial cells during atherogenesis. , 2003, Nutrition reviews.

[17]  Douglas L Mann,et al.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.

[18]  R. Califf,et al.  Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) , 2002, Circulation.

[19]  P. Calder,et al.  The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. , 2002, The American journal of clinical nutrition.

[20]  Peter L McLennan,et al.  Cardiac Membrane Fatty Acid Composition Modulates Myocardial Oxygen Consumption and Postischemic Recovery of Contractile Function , 2002, Circulation.

[21]  E. Benjamin,et al.  Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.

[22]  A. Feldman,et al.  Anti–Tumor Necrosis Factor-&agr; Antibody Limits Heart Failure in a Transgenic Model , 2001, Circulation.

[23]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[24]  K. Sliwa,et al.  Beneficial Effects of Pentoxifylline in Patients With Idiopathic Dilated Cardiomyopathy Treated With Angiotensin-Converting Enzyme Inhibitors and Carvedilol: Results of a Randomized Study , 2001, Circulation.

[25]  S. Nitter‐Hauge,et al.  Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure , 2001, Circulation.

[26]  C. Jones,et al.  Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. , 2000, Journal of the American College of Cardiology.

[27]  S. Frøland,et al.  CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes. , 2000, Cardiovascular research.

[28]  S. Frøland,et al.  Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. , 1999, Journal of the American College of Cardiology.

[29]  S. Frøland,et al.  Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1999, The American journal of cardiology.

[30]  E. Lakatta,et al.  PUFA and aging modulate cardiac mitochondrial membrane lipid composition and Ca2+ activation of PDH. , 1999, American journal of physiology. Heart and circulatory physiology.

[31]  P. Poole‐Wilson,et al.  Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. , 1998, QJM : monthly journal of the Association of Physicians.

[32]  A. Heagerty,et al.  Dietary supplementation with marine fish oil improves in vitro small artery endothelial function in hypercholesterolemic patients: a double-blind placebo-controlled study. , 1997, Circulation.

[33]  R. Doughty,et al.  Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease , 1997 .

[34]  A. Yeung,et al.  Close relation of endothelial function in the human coronary and peripheral circulations. , 1995, Journal of the American College of Cardiology.

[35]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[36]  G. D. Johnston,et al.  Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[37]  C. Benedict,et al.  Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. , 1994, The American journal of cardiology.

[38]  B. Lucchesi,et al.  Complement activation and inhibition in myocardial ischemia and reperfusion injury. , 1994, Annual review of pharmacology and toxicology.

[39]  T. Rector,et al.  Pulmonary and peripheral vascular factors are important determinants of peak exercise oxygen uptake in patients with heart failure. , 1993, Journal of the American College of Cardiology.

[40]  S. Yusuf,et al.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.

[41]  S. Yusuf,et al.  Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure , 1992, Circulation.

[42]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[43]  J. Wilson,et al.  Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. , 1984, Circulation.